|Day Low/High||0.06 / 0.06|
|52 Wk Low/High||0.04 / 3.46|
A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'
A debate about NPS Pharma, Gattex and the sustainability of orphan drug pricing with Forbes' Matt Herper
Dendreon Corporation (NASDAQ: DNDN) today announced the sale of its immunotherapy manufacturing facility (IMF) based in Morris Plains, New Jersey, to Novartis Pharmaceuticals Corporation for $43 million in cash.
Stimuvax failed to prolong survival in a large study of lung cancer patients.
Cell Therapeutics' Jim Bianco Wins! Amarin CEO Joe Zakrzewski tries to steal election with last-minute plot.
November 27, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: 2012 dbAccess BioFEST in Boston, MA, on December 4, 2012, at 2:15 p.
Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of Lindsay Rocco as executive vice president, corporate communications and member of the executive committee, effective immediately.
Provenge sales were light but no blowups left investors happier about Dendreon's future.
November 2, 2012 – Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2012.
Medivation's Xtandi jumps out of the launch gate with strong sales of $14 million.
Third-quarter earnings announcements have been rescheduled due to Hurricane Sandy.
October 29, 2012–Dendreon Corporation (Nasdaq: DNDN) today announced that in light of Hurricane Sandy, the Company has rescheduled the release of its third quarter 2012 earnings results.
A busy week for biotech earnings includes the first look at cancer drug launches from Onyx and Medivation.
October 5, 2012–Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Tuesday, October 30, 2012, at 9:00 a.
October 3, 2012 – Dendreon Corporation (NASDAQ:DNDN) today announced the company will be presenting at the MD Becker Partners’ 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking ...
September 27, 2012--Dendreon Corporation (NASDAQ: DNDN) today announced the first patient enrollment and initiation of treatment for the sipuleucel-T European Union (EU) open-label study.
Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Biotech trader Dan Rosenblum shows how to trade a controversial stock even if you lack strong conviction.
More data will help Peregrine convince skeptics that bavituximab is a real lung cancer drug.
August 24, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences: Stifel Nicolaus 2012 Global Healthcare Conference in Boston, MA, on ...
Twits. Prostate problems. Rogue comments by a UBS CEO and booted GM marketing honchos: It's time for this week's edition of Wall Street's dumbest.
Here is this week's roundup of the dumbest actions on Wall Street.
Here's a look at the technicals of some of the most actively traded stocks on the market today.
Provenge demand is slacking and no manner of cost cuts will bring Dendreon back from the precipice.
There's a lot not to like about most social media companies, Cramer said.
Shares of Dendreon (Nasdaq:DNDN) were gapping down Tuesday morning with an open price 18.6% lower than Monday's closing price. The stock closed at $6.18 yesterday and opened today's trading at $5.03.
Dendreon's CEO Discusses Q2 2012 Results - Earnings Call Transcript
July 30, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced a strategic restructuring plan designed to accelerate the Company’s path to profitability and future growth.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.